Page 24 - சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Trial to enrol up to 30,000 volunteers worldwide Fast Track designation granted by US FDA Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval from Canadian and US regulatory authorities to proceed with enrolment of healthy adults in the Phase 3 portion of the trial based on positive interim Phase 2 results. “We are pleased to take the significant step of initiating the Phase 3 clinical trial at sites around the world,” said Takashi Nagao, CEO and President of Medicago. “This brings us one step closer to delivering an important new COVID-19 vaccine and contributing to the global fight against the pandemic along with our partner GSK.”

United statesCarolyn finkleThomas breuerTakashi nagaoDrug administrationMelinda gates foundationData monitoring committeeQuebec cityChief medical officerFast trackChief operating officerEmergency use authorisationVir biotechnologyIndependent data monitoring committeeEmergency use authorizationஒன்றுபட்டது மாநிலங்களில்